Overview
PALI market data
Price History
PALI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$10.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -936.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.53 – $2.86 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $368.6M · P/B 2.71 · P/S 1,474.33.
Company News
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000KBenzinga · Aug 10, 2026, 9:05 PM
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative ColitisBenzinga · Jul 23, 2026, 6:06 PM
Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.Benzinga · Jul 23, 2026, 3:21 PM
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jul 23, 2026, 11:29 AM
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8Benzinga · Jul 23, 2026, 10:57 AM
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative ColitisBenzinga · Jun 29, 2026, 12:40 PM
8-K filing — PALISADE BIO, INC. (PALI)SEC EDGAR · Jun 11, 2026, 9:23 PM
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis SymposiumBenzinga · Jun 9, 2026, 12:50 PM
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga · May 27, 2026, 12:02 PM